glaumox
aft pharmaceuticals ltd - acetazolamide sodium 549.5mg equivalent to 500 mg acetazolamide; - powder for injection - 500 mg - active: acetazolamide sodium 549.5mg equivalent to 500 mg acetazolamide excipient: hydrochloric acid nitrogen sodium hydroxide - for adjunctive treatment of oedema due to congestive heart failure; drug-induced oedema;
lioresal
novartis new zealand ltd - baclofen 10mg; - tablet - 10 mg - active: baclofen 10mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose povidone wheat starch
lioresal intrathecal
novartis new zealand ltd - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
lioresal intrathecal
novartis new zealand ltd - baclofen 2 mg/ml - solution for injection - 10 mg/5ml - active: baclofen 2 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
baclofen sintetica
boucher & muir (new zealand) limited t/a bnm group - baclofen 0.5 mg/ml - solution for infusion - 0.5 mg/ml - active: baclofen 0.5 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
baclofen sintetica
boucher & muir (new zealand) limited t/a bnm group - baclofen 2 mg/ml - solution for infusion - 2 mg/ml - active: baclofen 2 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
baclofen sintetica
boucher & muir (new zealand) limited t/a bnm group - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
hydromorphon aristo akut 1,3 mg hartkapseln
hydromorphon aristo akut 2,6 mg hartkapseln
hydromorphon beta 1,3 mg hartkapseln